Annette Van Der Heyden

Don't miss it! It's time to organise your ✈️ and register 🛌 – at Melbourne, Victoria

Join in and let’s talk: “Unravelling PSMA Biology” 👉Live, Free & Interactive: link.prostic.org/webinar >750 already registered PSMA Theranostics is booming and it is only the beginning. Let’s unravel PSMA biology together. Join us for a free and an enlightening live session with world-renowned experts. Explore the next frontier in prostate cancer treatment a deep dive on many aspects of PSMA biology. What will be next? Keynote speakers: ◼ Himisha Beltran - Dana-Farber Cancer Institute ◼ Martin Pomper, M.D., Ph.D. - UT Southwestern Medical Center ◼ Louise Emmett - St Vincent's Health Australia ◼ Edmond Kwan - Monash University Hosted by: ◼ Michael Hofman - ProsTIC Theranostics ◼ Professor Declan Murphy - GU Cast | Urology Podcast ◼ Dr James Buteau - Peter MacCallum Cancer Centre ◼ Howard Soule - Prostate Cancer Foundation ◼ Andrea Miyahira - Prostate Cancer Foundation

We are seeking a clinical trial co-ordinator who wants to make a true impact... at @PeterMacCC . you’ll lead the coordination of our @pros_tic clinical trials, building on more than a decade of global leadership in cutting-edge research. Why Join Us? ⦿ Global Recognition: We lead landmark trials like the ProPSMA study (Lancet 2020) cited over 1,800 times! ⦿ Innovative Research: Our portfolio spans novel diagnostic PET imaging and targeted therapies, from first-in-human to Phase III trials. ⦿ Professional Growth: Work alongside world-leading researchers, and medical imaging experts in a dynamic, collaborative environment. Apply here: careers.petermac.org/job/MEL… Find out more about us at petermac.org/prostic

@pros_tic is looking for an Administrative Officer @PeterMacCC! You'll play a key role in managing admin tasks, grant applications, travel coordination, reimbursements, and keeping our social media active (website, @LinkedIn , @YouTube, @X). You'll also help organize international conferences, workshops & webinars — ensuring our research reaches those who need it most. Work directly with me & our Program Manager, @AnnetteVDHeyden, supporting a team at the forefront of prostate cancer research. Help drive innovation & improve patient outcomes! 🔗 Apply now: careers.petermac.org/job/MEL… 🔬 Learn more: petermac.org/prostic

Twenty cycles (that's right 20) of Lutetium-177 PSMA-617 for metastatic castration-resistant cancer!! Check our case report just published in @JournalofNucMed jnm.snmjournals.org/content/… Current randomized controlled data demonstrate the safety and efficacy of 6 cycles of [¹⁷⁷Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial, 15 of 30 patients received additional cycles; 11 (73%) had a subsequent prostate-specific antigen (PSA) decline of 50% or more. A German multicenter study also supported extended therapy in 111 patients, with a median survival of 31.1 mo from the first administration and no increase in grade 3–4 toxicities. We describe safety and efficacy in a patient who received 20 cycles of [¹⁷⁷Lu]Lu-PSMA-617, receiving a total administered radioactivity of 129 GBq over 5 y. Initially diagnosed at age 59 with de novo bone-only metastatic prostate cancer and a PSA of 96 ug/L, he underwent intermittent androgen deprivation therapy for 13 y before requiring palliative radiotherapy for painful bone metastases. The following year, he was treated with 6 cycles of docetaxel, followed by 18 mo of enzalutamide. On progression with a PSA of 195 ug/L and a doubling time of 3.0 mo, the patient received 6 cycles of [¹⁷⁷Lu]Lu-PSMA-617, with a PSA nadir of 3.2 ug/L, as part of the TheraP trial. Paired PSMA PET/CT (SUVmax, 73; SUVmean, 10.7) and 18F-FDG PET/CT (metabolic tumor volume, 14 cm3) at enrollment had favorable characteristics. A second treatment block of 2 cycles of [¹⁷⁷Lu]Lu-PSMA-617 was given 266 d after cycle 6 (14 mo after cycle 1) on a clinical registry, resulting in a PSA decline of more than 90% (nadir, 14.2 ug/L) and a further treatment break of 229 d. The treatment-free interval remained similar between treatment blocks 2 and 3 at 216 d; however, this interval shortened to 75 and 78 d between blocks 4 and 5 and blocks 5 and 6, respectively (see Figure). After cycle 15, he continued to receive symptomatic benefit, but on-treatment biochemical and imaging progression emerged. The hemoglobin and platelet nadirs were 98 g/L and 115 × 109/L, respectively, occurring after cycle 18. Renal function remained normal, with an estimated glomerular filtration rate of 92 mL/min after cycle 20, compared with 117 mL/min at baseline, and an estimated cumulative kidney dose of 55.5 Gy. This exceeds the 23-Gy maximum tolerated dose defined by external-beam radiotherapy, highlighting the limitation of extrapolating external-beam radiotherapy normal-organ constraints to radiopharmaceutical therapy. Grade 1 xerostomia occurred from cycle 3 and remained mild and transient, usually lasting a few days after many, but not all, cycles. After cycle 20, he received 2 cycles of cabazitaxel and had a clinical response but subsequently progressed with new brain metastases and physical decline; he died 2 mo later at age 81, 4.9 y after the initiation of [¹⁷⁷Lu]Lu-PSMA-617. In conclusion, in selected patients, [¹⁷⁷Lu]Lu-PSMA-617 appears to have substantial benefits beyond 6 cycles. @DrKerryJewell @ButeauJames @EdmondMKwan @liz_medhurst @SandhuShahneen @AzadOncology

Really wonderful to host nuclear medicine and medical oncology colleagues from Argentina and deep dive into all aspects of PSMA PET and theranostics @PeterMacCC. @jpsade2: please help add X/twitter tags for others

✨ Wrapping up another incredible @PCF_Science #PCFRetreat24! 🙏It was an honor to organize "New Atoms, New Targets" diving into the future of theranostics with an outstanding lineup of experts. 🔹 @drlouiseemmett what's hot in 2024🔥 🔹 @LewisLabMSKCC new atoms☢️ 🔹 @AarmstrongDuke new targets🚀 🔹 @ButeauJames what's coming in 2025-6 💡Highlights: looking back in history at Dr Saul Hertz' discovery of radio-iodine to see the future of curative theranostics, three new randomised trials published in 2024 (and the year is not finished), so many new targets being explored, the whole period table with PET, SPECT, alpha, beta & Auger emitters waiting to be explored. @soulehoward1 @AndreaMiyahira @pros_tic @PeterMacCC